*** This is not an investment advice****

We are not a research firm to provide members with in depth research analyst, we trade based on catalyst, make money and move on to the next. With biotech, I find no matter how in depth due diligence you do there is always a risky side. Be nibble  with your positions, don’t trade big in size and feel trapped with your capital. Success traders they succeed because of small consistency gain compounding up over time.

Sanofi (SNY) big pharm company looking for potential rare disease to beat their competition. Here are some speculative play to watch or play.

  1. ALNY Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference.
     2. MyoKardia, Inc (MYOK)- a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases.

3. Bellicum Pharmaceuticals, Inc. (BLCM)- a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally

  • Sanofi does not have any stake in this company
  • FDA grants Orphan Drug Designation (ODD) for BPX-501 therapy
  • Earning program updates webcast will be on Monday, 3/14 after market close. We will know more
  • Catalyst: ASCO in June.  BPX-401 is expected to enter the clinic in the first half of 2016.
  • Last earning updates stock pop 20%+ on Pediatric patients with beta thalassemia, SCID.